Sanofi SVP to become president and CEO of Teva Europe

Senior vice president, generic strategy and development, at Sanofi, Dr Rob Koremans, has been appointed president and CEO of Teva Europe.

Koremans will begin his new position in March 2012, when he will take over from Dr Gerard van Odijk who has held both positions for six years.

Van Odijk will remain with the company for the rest of 2012 to help with the transition.

Shlomo Yanai, who is to step down from his current position of president and CEO of Teva Pharmaceutical in May, commented on the announcement.

He said: “Under [van Odijk's] management, our business in Europe has been transformed as Teva became the undisputed generics leader in this major and growing market and established a strong position in speciality pharmaceuticals.

“I am very confident that Rob Koremans, together with our strong European management, will continue our success story across Europe.”

Prior to his current position at Sanofi, Koremans was CEO at Zentiva, the European generics business for Sanofi.

He has also been CEO of Cryo-Save, the stem cell storage company, and was vice president, Europe, of the Serono Group.